Open AccessPreclinical study of 212Pb alpha-radioimmunotherapy targeting CD20 in non-Hodgkin lymphoma
Author(s) -
Stéphanie Durand-Panteix,
Jacques Monteil,
Magali Sage,
Armand Garot,
M. Clavel,
Amal Saidi,
Julien Torgue,
Michel Cogné,
Isabelle Quelven
Publication year - 2021
Publication title -
british journal of cancer
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.833
H-Index - 236
eISSN - 1532-1827
pISSN - 0007-0920
DOI - 10.1038/s41416-021-01585-6
Subject(s) - radioimmunotherapy , rituximab , lymphoma , medicine , biodistribution , cd20 , in vivo , spleen , cancer research , immunology , oncology , monoclonal antibody , antibody , biology , microbiology and biotechnology
Despite therapeutic advances, Non-Hodgkin lymphoma (NHL) relapses can occur. The development of radioimmunotherapy (RIT) with α-emitters is an attractive alternative. In this study, we investigated the potential of α-RIT in conjunction with 212 Pb-rituximab for the treatment of NHL.